Showing 611-620 of 725 results for "".
- Murad Names Fred Gysi Chief Financial Officerhttps://practicaldermatology.com/news/20121115-murad_names_fred_gysi_chief_financial_officer/2459682/Fred Gysi now serves as Chief Financial Officer for Murad. In this role, Gysi will be responsible for financial reporting, budgeting, treasury and cash flow management, financial and marketing analysis, and strategic planning. Gysi comes to Murad w
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand
- Baricitinib Enhances Phototherapy Efficacy in Adults with Active Vitiligohttps://practicaldermatology.com/news/baricitinib-enhances-phototherapy-efficacy-in-severe-atopic-dermatitis/2471046/Baricitinib combined with narrowband UV-B achieved a modest reduction in disease severity in adults with severe, active nonsegmental vitiligo, but did not meet the prespecified threshold for sufficient repigmentation, new research revealed. The trial enrolled 49 adul
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Cellulite Reduction Seen With Cellfina Lasts Five Yearshttps://practicaldermatology.com/news/cellulite-reduction-seen-with-cellfina-lasts-five-years/2457566/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. This new data b
- New Applicator Suggests Cryolipolysis May Be an Option for Male Pseudogynecomastiahttps://practicaldermatology.com/news/new-applicator-suggests-cryolipolysis-may-be-an-option-for-male-pseudogynecomastia/2457678/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent study in Lasers in Surgery and Medicine (LSM). “This split-b
- Lancer Skincare Launches At-Home Producthttps://practicaldermatology.com/news/20130117-lancer_skincare_launches_at-home_product/2459635/The Lancer Skincare collection now includes the Microcurrent Powerboost, a hand-held device to help tone, tighten, and correct imbalances in the skin. According to the company, the Microcurrent Powerboost allows daily skincare products to b
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B